• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Dig Endosc . SARS-CoV-2 prevalence in saliva and gastric and intestinal fluid in patients undergoing gastrointestinal endoscopy in COVID-19 endemic

tetano

Editor, Senior Moderator
Dig Endosc


. 2021 Feb 6.
doi: 10.1111/den.13945. Online ahead of print.
SARS-CoV-2 prevalence in saliva and gastric and intestinal fluid in patients undergoing gastrointestinal endoscopy in COVID-19 endemic areas: prospective cross-sectional study in Japan


Shigeta Miyake[SUP] 1 [/SUP], Keiichi Ashikari[SUP] 2 [/SUP], Shingo Kato[SUP] 2 3 [/SUP], Tomohiro Takatsu[SUP] 2 [/SUP], Hirofumi Kuwashima[SUP] 4 [/SUP], Hiroaki Kaneko[SUP] 4 [/SUP], Koki Nagai[SUP] 2 [/SUP], Ikue Watari[SUP] 2 [/SUP], Takamitsu Sato[SUP] 2 [/SUP], Yutaro Yamaoka[SUP] 5 6 [/SUP], Tetsuya Yamamoto[SUP] 1 [/SUP], Akihide Ryo[SUP] 5 [/SUP], Shin Maeda[SUP] 4 [/SUP], Atsushi Nakajima[SUP] 2 [/SUP], Takuma Higurashi[SUP] 2 [/SUP]



Affiliations

Abstract

Objectives: Gastrointestinal endoscopy (GIE) is useful for the early detection and treatment of many diseases; however, GIE is considered a high-risk procedure in the coronavirus disease 2019 (COVID-19) pandemic era. This study aimed to explore the rate of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) positivity in saliva and gastrointestinal fluids to which endoscopy medical staff are exposed.
Methods: The study was a single-center cross-sectional study. From June 1 to July 31, 2020, all patients who underwent GIE at Yokohama City University Hospital were registered. All patients provided 3 ml of saliva. For upper GIE, 10 ml of gastric fluid was collected through the endoscope. For lower GIE, 10 ml of intestinal fluid was collected through the endoscope. The primary outcome was the positive rate of SARS-CoV-2 in saliva and gastrointestinal fluids. We also analyzed serum-specific antibodies for SARS-CoV-2 and patients' background information.
Results: A total of 783 samples (560 upper GIE and 223 lower GIE samples) were analyzed. Polymerase chain reaction (PCR) on saliva samples did not show any positive results in either upper or lower GIE samples. However, 2.0% (16/783) of gastrointestinal fluid samples tested positive for SARS-CoV-2. No significant differences in age, sex, purpose of endoscopy, medication, or rate of antibody test positivity were found between PCR positive and PCR negative cases.
Conclusions: Asymptomatic patients, even those with no detectable virus in their saliva, had SARS-CoV-2 in their gastrointestinal tract. Endoscopy medical staff should be aware of infection when performing procedures. The study was registered as UMIN000040587.

Keywords: COVID-19; SARS-CoV-2; endoscopy; gastrointestinal fluid; saliva.
 
Back
Top Bottom